KRAS MUTATION-RELATED TUMORS
Clinical trials for KRAS MUTATION-RELATED TUMORS explained in plain language.
Never miss a new study
Get alerted when new KRAS MUTATION-RELATED TUMORS trials appear
Sign up with your email to follow new studies for KRAS MUTATION-RELATED TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets 'Undruggable' cancer mutations in major trial
Disease control Recruiting nowThis study is testing a new oral drug, S241656, alone and in combination with other cancer therapies. It aims to find a safe and effective dose for adults with advanced cancers, including lung, pancreatic, and colorectal cancers, that have specific genetic mutations like KRAS or …
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Early trial tests new drug combo for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing the safety and finding the right dose of a new drug combination (NEROFE plus doxorubicin) for people with advanced solid tumors that have specific genetic markers (KRAS mutation and ST2-positive). It will enroll 24 participants who have run out o…
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase: PHASE1 • Sponsor: Georgetown University • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC